New concepts in hypertrophic cardiomyopathies, part II

Circulation

Volumn 104, Issue 18, 2001, Pages 2249-2252

  Roberts, Robert ^a   Sigwart, Ulrich ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cardiomyopathy; Genetics; Hypertrophy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; METHOXAMINE; NITRATE; VERAPAMIL;

CLINICAL FEATURE; DEFIBRILLATOR; HEART SURGERY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035975966     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4301.097430     Document Type: Review

References (37)

1. The management of hypertrophic cardiomyopathy
2. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy
3. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study
4. Hypertrophic cardiomyopathy: The importance of the site and the extent of hypertrophy: A review
5. Functional obstruction of the left ventricle
6. Asymmetrical hypertrophy of the heart in young adults
7. Asymmetrical septal hypertrophy (ASH): Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS
8. Systolic anterior motion of the posterior mitral leaflet: A previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy
9. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology and therapy (second of two parts)
10. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy
11. Hypertrophic subaortic stenosis: Operative methods utilized to relieve left ventricular outflow obstruction
12. Hypertrophic cardiomyopathy (HCM): Surgical versus drug therapy
13. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy
14. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: Studies to develop a new catheter-based concept of treatment
15. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients
16. Nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor experience (1996-1999)
17. Perspectives on the role of new treatment strategies in hypertrophic cardiomyopathy
18. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography
19. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
20. Percutaneous transluminal septal myocardial ablation: A new treatment for hypertrophic obstructive cardiomyopathy
21. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy
22. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy
23. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic obstructive cardiomyopathy
24. A computer model of cardiac electrical activity for the simulation of arrhythmias
25. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgment?
26. Hypertrophic cardiomyopathy and sudden death
27. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients
28. Hypertrophic cardiomyopathy and sudden death: New perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator
29. Tissue microarrays for high-throughput molecular profiling of tumor specimens
30. Mass spectrometry and proteomics
31. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
32. A transgenic rabbit model for human hypertrophic cardiomyopathy
33. A mouse model of familial hypertrophic cardiomyopathy
34. Purkinje-muscle reentry as a mechanism of polymorphic ventricular arrhythmias in a 3-dimensional model of the ventricles
35. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy
36. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy
37. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy